The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET™) showed that the angiotensin II receptor blocker (ARB) telmisartan was as protective as the reference-standard ramipril in a broad cross-section of patients at increased cardiovascular risk, but was better tolerated. Telmisartan has a unique profile among ARBs, with a high affinity for the angiotensin II type 1 receptor, a long duration of receptor binding, a high lipophilicity and a long plasma half life. This leads to sustained and powerful blood pressure lowering when compared with the first marketed ARBs, such as losartan and valsartan. Some pharmacological properties of telmisartan clearly distinguish it from other members of the ARB class and may contribute to the clinical effects seen with telmisartan. A class effect for ARBs cannot be assumed. To date, telmisartan is the only ARB that has been shown to reduce cardiovascular risk in at-risk cardiovascular patients.
YusufSTeoKKPogueJ: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med2008; 358: 1547–1559.
2.
JuliusSKjeldsenSEWeberM: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet2004; 363: 2022–2031.
3.
DahlöfBDevereuxRBKjeldsenSE: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet2002; 359: 995–1003.
4.
RiesUJMihmGNarrB: 6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: Synthesis, biological activity, and structure-activity relationships. J Med Chem1993; 36: 4040–4051.
5.
KurtzTWPravenecM: Molecule-specific effects of angiotensin II-receptor blockers independent of the renin-angiotensin system. Am J Hypertens2008; 21: 852–859.
6.
HunyadyLCattKJ: Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol2006; 20: 953–970.
7.
WienenWEntzerothMvan MeelJCA: A review on telmisartan: A novel, long-acting angiotensin II-receptor antagonist. Cardiovasc Drug Rev2000; 18: 127–156.
8.
MaillardMPPerregauxCCentenoC: In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist. J Pharmacol Exp Ther2002; 302: 1089–1095.
9.
WienenWHauelNvan MeelJC: Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol1993; 110: 245–252.
10.
KakutaHSudohKSasamataM: Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: Comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res2005; 25: 41–46.
11.
LeMTPugsleyMKVauquelinG: Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor. Br J Pharmacol2007; 151: 952–962.
12.
WienenWEntzerothMvan MeelJ: A review on telmisartan: A novel, long-acting angiotensin II-receptor antagonist. Cardiovasc Drug Rev2000; 18: 127–154.
13.
StangierJSuCAPFRothW: Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res2000; 28: 149–167.
14.
SongJCWhiteCM: Olmesartan medoxomil (CS-866). An angiotensin II receptor blocker for treatment of hypertension. Formulary2001; 36: 487–499.
15.
BurnierMBrunnerHR: Angiotensin II receptor antagonists. Lancet2000; 355: 637–645.
16.
BrunnerHR: The new oral angiotensin II antagonist olmesartan medoxomil: A concise overview. J Hum Hypertens2002; 16 (suppl 2): S13–S16.
17.
StangierJSuC-APFvan HeiningenPNM: Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge. J Cardiovasc Pharmacol2001; 38: 672–685.
18.
StangierJSchmidJTürckD: Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers. J Clin Pharmacol2000; 40 (12 pt 1): 1312–1322.
19.
IsrailiZH: Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens2000; 14 (suppl 1): S73–S86.
20.
EbnerTHeinzelGProxA: Disposition and chemical stability of telmisartan 1-O-acylglucuronide. Drug Metab Dispos1999; 27: 1143–1149.
21.
RossR: Atherosclerosis is an inflammatory disease. Am Heart J1999; 138 (5 pt 2): S419–S420.
22.
MaunoVHannuKEskoK: Proinflammation and hypertension: A population-based study. Mediators Inflamm2008; 2008:619–704 (doi:10.1155/2008/619704).
23.
EkholmMKahanTJörneskogG: Angiotensin II infusion in man is proinflammatory but has no short-term effects on thrombin generation in vivo. Thromb Res2009; 124: 110–115.
24.
SuzukiYRuiz-OrtegaMLorenzoO: Inflammation and angiotensin II. Int J Biochem Cell Biol2003; 35: 881–900.
25.
NagaiNIzumi-NagaiKOikeY: Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-κB pathway. Invest Ophthalmol Vis Sci2007; 48: 4342–4350.
26.
TakaiSKirimuraKJinD: Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling. Hypertens Res2005; 28: 593–600.
27.
TakayaTKawashimaSShinoharaM: Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. Atherosclerosis2006; 186: 402–410.
28.
JungKHChuKLeeST: Blockade of AT1 receptor reduces apoptosis, inflammation, and oxidative stress in normotensive rats with intracerebral hemorrhage. J Pharmacol Exp Ther2007; 322: 1051–1058.
29.
KaschinaESchraderFSommerfeldM: Telmisartan prevents aneurysm progression in the rat by inhibiting proteolysis, apoptosis and inflammation. J Hypertens2008; 26: 2361–2373.
30.
UsuiTSugisakiKIriyamaA: Inhibition of corneal neovascularization by blocking the angiotensin II type 1 receptor. Invest Ophthalmol Vis Sci2008; 49: 4370–4376.
31.
ThaiHWollmuthJGoldmanS: Angiotensin subtype 1 receptor (AT1) blockade improves vasorelaxation in heart failure by upregulation of endothelial nitric-oxide synthase via activation of the AT2 receptor. J Pharmacol Exp Ther2003; 307: 1171–1178.
CianchettiSDel FiorentinoAColognatoR: Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclerosis2008; 198: 22–28.
34.
BlessingEPreuschMKranzhoferR: Antiatherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice. Atherosclerosis2008; 199: 295–303.
35.
ChujoDYagiKAsanoA: Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients. Hypertens Res2007; 30: 1205–1210.
36.
YanoYHoshideSIshikawaJ: The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients. Am J Hypertens2007; 20: 565–572.
37.
HongSJShimWJChoiJI: Comparison of effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients. Am J Cardiol2007; 100: 1625–1629.
38.
PrasadK: C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev2006; 24: 33–50.
39.
NakayamaSWatadaHMitaT: Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension. Hypertens Res2008; 31: 7–13.
40.
LuknarMGoncalvesovaELesnyP: Telmisartan and metabolic syndrome after heart transplantation. Clin Transplant2009; (doi 10.1111/j.1399–0012.2009.00979.x) [e-pub ahead of print].
41.
BensonSCPershadsinghHAHoCI: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension2004; 43: 993–1002.
ErbeDVGartrellKZhangY-L: Molecular activation of PPARγ by angiotensin II type 1-receptor antagonists. Vascul Pharmacol2006; 45: 154–162.
44.
CombsTPWagnerJABergerJ: Induction of adipocyte complement-related protein of 30 kilodaltons by PPARγ agonists: A potential mechanism of insulin sensitization. Endocrinology2002; 143: 998–1007.
45.
YangWSJengCYWuTJ: Synthetic peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care2002; 25: 376–380.
46.
MakitaSAbikoANaganumaY: Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance. Metabolism2008; 57: 1473–1478.
47.
YamadaSAnoNTodaK: Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro. Hypertens Res2008; 31: 601–606.
48.
NegroRFormosoGHassanH: The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients. J Endocrinol Invest2006; 29: 957–961.
49.
MoriuchiAYamasakiHShimamuraM: Induction of human adiponectin gene transcription by telmisartan, angiotensin receptor blocker, independently on PPAR-γ activation. Biochem Biophys Res Commun2007; 356: 1024–1030.
50.
BodenGLaaksoM: Lipids and glucose in type 2 diabetes: What is the cause and effect?Diabetes Care2004: 27: 2253–2259.
51.
MichelMCBohnerHKosterJ: Safety of telmisartan in patients with arterial hypertension: An open-label observational study. Drug Saf2004; 27: 335–344.
52.
InoueTMorookaTMoroeK: Effect of telmisartan on cholesterol levels in patients with hypertension–Saga Telmisartan Aggressive Research (STAR). Horm Metab Res2007; 39: 372–376.
53.
MoriYItohYTajimaN: Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes. Adv Ther2007; 24: 146–153.
54.
SanchezRAMasnattaLDPesineyC: Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives. J Hypertens2008; 26: 2393–2398.
55.
YamanaAAritaMFurutaM: The angiotensin II receptor blocker telmisartan improves insulin resistance and has beneficial effects in hypertensive patients with type 2 diabetes and poor glycemic control. Diabetes Res Clin Pract2008; 82: 127–131.
56.
HinoiTTomohiroYKajiwaraS: Telmisartan, an angiotensin II type 1 receptor blocker, improves coronary microcirculation and insulin resistance among essential hypertensive patients without left ventricular hypertrophy. Hypertens Res2008; 31: 615–622.
57.
ZanchiADullooAGPerregauxC: Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing properties. Am J Physiol Endocrinol Metab2007; 293: E91–E95.
58.
VitaleCMercuroGCastiglioniC: Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol2005; 4: 6.
59.
BahadirOUzunluluMOguzA: Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome. Hypertens Res2007; 30: 49–53.
60.
IchikawaY: Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome. Intern Med2007; 46: 1331–1336.
61.
DerosaGFogariED'AngeloA: Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. J Clin Pharm Ther2007; 32: 261–268.
62.
SchiffrinELAmiriFBenkiraneK: Peroxisome proliferator-activated receptors: Vascular and cardiac effects in hypertension. Hypertension2003; 42: 664–668.
63.
DelerivePGervoisPFruchartJC: Induction of IκBα expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-α activators. J Biol Chem2000; 275: 36703–36707.
64.
BierhausAHofmannMAZieglerR: AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res1998; 37: 586–600.
65.
YamagishiSMatsuiTNakamuraK: Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-γ activation. Protein Pept Lett2008; 15: 850–853.
66.
NakamuraKYamagishiSNakamuraY: Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc Res2005; 70: 137–141.
67.
TianQMiyazakiRIchikiT: Inhibition of tumor necrosis factor-α-induced interleukin-6 expression by telmisartan through cross-talk of peroxisome proliferator-activated receptor-γ with nuclear factor κB and CCAAT/enhancer-binding protein-β. Hypertension2009; 53: 798–804.
68.
YoshidaTYamagishiSNakamuraK: Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-γ activation. Diabetologia2006; 49: 3094–3099.
69.
WeyandCMYoungeBRGoronzyJJ: T cells in arteritis and atherosclerosis. Curr Opin Lipidol2008; 19: 469–477.
70.
WalcherDHessKHeinzP: Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-γ. Hypertension2008; 51: 259–266.
71.
DzauV. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens2005, 23 (suppl 1): S9–S17.
72.
DzauVJAntmanEMBlackHR: The cardiovascular disease continuum validated: Clinical evidence of improved patient outcomes: Part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease)Circulation2006; 114: 2850–2870.
73.
DellesCKlingbeilAUSchneiderMP: The role of nitric oxide in the regulation of glomerular haemodynamics in humans. Nephrol Dial Transplant2004; 19: 1392–1397.
74.
KomersRKomersovaKKazdovaL: Effect of ACE inhibition and angiotensin AT1 receptor blockade on renal and blood pressure response to L-arginine in humans. J Hypertens2000; 18: 51–59.
75.
SchmiederREDellesCMimranA: Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care2007; 30: 1351–1356.
76.
TomiyamaHYamadaJKojiY: Effect of telmisartan on forearm postischemic hyperemia and serum asymmetric dimethylarginine levels. Am J Hypertens2007; 20: 1305–1311.
77.
IkejimaHImanishiTTsujiokaH: Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-γ-modulating activity, on nitric oxide bioavailability and atherosclerotic change. J Hypertens2008; 26: 964–972.
78.
VingerhoedtNMGillesRHowesJB: Haemodynamic and pulse wave responses to intravenous infusions of angiotensin II during chronic telmisartan therapy in normal volunteers. J Renin Angiotensin Aldosterone Syst2003; 4: 244–248.
79.
AsmarRGossePTopouchianJ: Effects of telmisartan on arterial stiffness in type 2 diabetes patients with essential hypertension. J Renin Angiotensin Aldosterone Syst2002; 3: 176–180.
80.
MallionJMSichéJPLacourcièreY: ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens1999; 13: 657–664.
81.
LittlejohnTMroczekWMarburyT: A prospective, randomized, open-label trial comparing telmisartan 80 mg and valsartan 80 mg in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Can J Cardiol2000; 16: 1123–1132.
82.
SmithDHCramerMJNeutelJM: Comparison of telmisartan versus losartan: Meta-analysis of titration-to-response studies. Blood Press Monit2003; 8: 111–117.
83.
LacourcièreYKrzesinskiJMWhiteWB: Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit2004; 9: 203–210.
84.
DingPYChuKMChiangHT: A double-blind ambulatory blood pressure monitoring study of the efficacy and tolerability of once-daily telmisartan 40 mg in comparison with losartan 50 mg in the treatment of mild-to-moderate hypertension in Taiwanese patients. Int J Clin Pract Suppl2004; 58: 16–22.
85.
CalvoCHermidaRCAyalaDE: Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension. J Hypertens2004; 22: 837–846.
86.
ZhuJRBaiJCaiNS: Efficacy and safety of telmisartan vs. losartan in control of mild-to-moderate hypertension: A multicentre, randomised, double-blind study. Int J Clin Pract Suppl2004; 58: 46–49.
87.
NishimuraTHashimotoJOhkuboT: Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements. Clin Exp Hypertens2005; 27: 477–489.
88.
BarnettAHBainSCBouterP: Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med2004; 351: 1952–1961.
89.
MontecuccoFPendeAMachF: The renin-angiotensin system modulates inflammatory processes in atherosclerosis: Evidence from basic research and clinical studies. Mediators Inflamm2009; 2009. 752406 (doi:10.1155/2009/752406).
90.
GalleJSchwedhelmEPinnettiS: Antiproteinuric effects of angiotensin receptor blockers: Telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant2008; 23: 3174–3183.
91.
PanchapakesanUSumualSPollockCA: PPARγ agonists exert antifibrotic effects in renal tubular cells exposed to high glucose. Am J Physiol Renal Physiol2005; 289: F1153–F1158.
92.
BrennerBMCooperMEde ZeeuwD: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med2001; 345: 861–869.
93.
ParvingHHLehnertHBröchner-MortensenJ: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med2001; 345: 870–878.
94.
MakinoHHanedaMBabazonoT: Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care2007; 30: 1577–1578.
95.
LacourcièreYBelangerAGodinC: Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int2000; 58: 762–769.
96.
BakrisGBurgessEWeirM: Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int2008; 74: 364–369.
97.
KannelWB: Left ventricular hypertrophy as a risk factor in arterial hypertension. Eur Heart J1992; 13 (suppl D): 82–88.
98.
BouzegrhaneFThibaultG: Is angiotensin II a proliferative factor of cardiac fibroblasts?Cardiovasc Res2002; 53: 304–312.
99.
MattioliAVBonattiSMonopoliD: Influence of regression of left ventricular hypertrophy on left atrial size and function in patients with moderate hypertension. Blood Press2005; 14: 273–278.
100.
GalzeranoDTammaroPDel ViscovoL: Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study. Am J Hypertens2005; 18 (12 pt 1): 1563–1569.
101.
PetrovicJPetrovicDVukovicN: Ventricular and vascular remodelling–effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients. J Int Med Res2005; 33 (suppl 1): 39A–49A.
102.
GalzeranoDTammaroPCercielloA: Freehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: A multicentre study. J Hum Hypertens2004; 18: 53–59.
103.
BurlewBSWeberKT: Connective tissue and the heart. Functional significance and regulatory mechanisms. Cardiol Clin2000; 18: 435–442.
104.
NakashimaHKumagaiKUrataH: Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation2000; 101: 2612–2617.
105.
GoetteAStaackTRockenC: Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol2000; 35: 1669–1677.
106.
StewartSHartCLHoleDJ: A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med2002; 113: 359–364.
107.
GalzeranoDCaselliSBreglioR: A multicentre, randomized study comparing efficacy of telmisartan versus carvedilol in preventing atrial fibrillation recurrence in hypertensive patients. Circulation2007; 116 (suppl II): 556–557 [abstract].
108.
HealeyJSBaranchukACrystalE: Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A meta-analysis. J Am Coll Cardiol2005; 45: 1832–1839.
109.
MadridAHBuenoMGRebolloJM: Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A prospective and randomized study. Circulation2002; 106: 331–336.
110.
WachtellKLehtoMGerdtsE: Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol2005; 45: 712–719.
111.
MaggioniAPLatiniRCarsonPE: Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J2005; 149: 548–557.
112.
CelikTIyisoyAKursakliogluH: The comparative effects of telmisartan and ramipril on P-wave dispersion in hypertensive patients: A randomized clinical study. Clin Cardiol2005; 28: 298–302.
113.
Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med2000; 342: 145–153.
114.
YusufSTeoKAndersonC: Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial. Lancet2008; 372: 1174–1183.
115.
YusufSDienerHCSaccoRL: Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med2008; 359: 1225–1237.
116.
SmithDH: Dose-response characteristics of olmesartan medoxomil and other angiotensin receptor antagonists. Am J Cardiovasc Drugs2007; 7: 347–356.
